web analytics
0.1 C
Munich
Saturday, December 3, 2022

Aphria Inc (OTCMKTS: APHQF) Continues to Dominate

Aphria Inc (OTCMKTS: APHQF) continues to dominate the markets moving up an incredible 60% plus in the last week alone and is currently nearing its all-time highs of $19.869. Aphria has transformed into a volume leader and is currently among the top few most traded cannabis stocks on the planet.

Aphria holds a commanding position in the Canadian cannabis industry currently undergoing rapid growth; Cannabis stocks are booming and have easily outpaced the broader markets this year and for good reason; the recreational cannabis market is projected to expand at a compound annual growth rate of 19.75% over the next decade, easily making it among the fastest growing areas of the global economy by a wide margin. Legal marijuana sales are expected to grow to more than $20 billion by 2022 according to Marijuana Business Daily. As October 17 looms closer Canadian MJ stocks have been heating up big time.

Aphria Inc (TSX:APH) (OTCMKTS: APHQF) is a Canadian cannabis company licensed to produce and sell medical cannabis under the provisions of the Access to Cannabis for Medical Purposes Regulations(“ACMPR”) located in Leamington, Ontario, the greenhouse capital of Canada.

The Company describes itself as a leading global cannabis company driven by an unrelenting commitment to our people, product quality and innovation. Headquartered in Leamington, Ontario – the greenhouse capital of Canada – Aphria has been setting the standard for the low-cost production of safe, clean and pure pharmaceutical-grade cannabis at scale, grown in the most natural conditions possible. Focusing on untapped opportunities and backed by the latest technologies, Aphria is committed to bringing breakthrough innovation to the global cannabis market. The Company’s portfolio of brands is grounded in expertly-researched consumer insights designed to meet the needs of every consumer segment. Rooted in our founders’ multi-generational expertise in commercial agriculture, Aphria drives sustainable long-term shareholder value through a diversified approach to innovation, strategic partnerships and global expansion, with a presence in more than 10 countries across 5 continents.

Currently Aphria is expanding its facility in Leamington, Ontario. work continues to rapidly advance on the 700,000-square-foot Part IV expansion, which Aphria anticipates will have its first sale early next year. The Part III expansion added 200,000 square feet of production space and more than tripled Aphria’s production capacity from 9,000 kg annually to 30,000 kg annually. When completed early next year, the fully expanded facility (referred to as Aphria One) will provide over 1,000,000 square feet of production space with an annualized capacity of 100,000 kg. Combined with the Company’s Double Diamond Farms location (referred to as Aphria Diamond) and its B.C.-based subsidiary Broken Coast Cannabis, Aphria’s fully-funded production capacity is anticipated to be approximately 230,000 kg per year by early 2019.

Aphria was founded in 2014 by Cole Cacciavillani and John Cervini, who were Leamington greenhouse operators. Vic Neufeld, formerly CEO of Jamieson Laboratories, a Canadian vitamin company stepped in as CEO of Aphria. The Company was granted a license to produce and sell medical cannabis by Health Canada in 2014 and made its first wholesale shipments in April 2015.

To Find out the inside Scoop on APHQF Subscribe to Microcapdaily.com Right Now by entering your Email in the box below

Much of Aprhias growth has come through acquisition; earlier this year Aphria closed the previously announced acquisition of Broken Coast Cannabis Inc. for $230 million in cash and stock. Broken Coast operates a fully licensed, purpose-built, indoor cannabis production facility on Vancouver Island. As part of the Transaction, Aphria approved the immediate commencement of Broken Coast’s Phase IV expansion, which will increase the facility’s annual capacity from 4,500 kg per year to 10,500 kg per year. First product sale are anticipated to occur in early 2019.

In July Aphria Inc. announced the Company’s planned expansion into Latin America and the Caribbean with the proposed acquisition of industry-leading companies in Colombia, Argentina, Jamaica and a right of first offer and refusal in respect of Brazil through a definitive share purchase agreement with Scythian Biosciences Inc. Also this year Aphria acquired Nuuvera, a Brampton-based cannabis company, for $826 million. Nuuvera was purchased in part due to its market position internationally, especially in Germany and Italy.

Earlier this year Aphia announced a $55 million capital project to build a state-of-the-art Extraction Centre in Leamington, ON. The facility will be equipped to conduct a wide range of cannabis extractions, including C02, butane and ethanol, and produce world-class cannabis concentrates, including fractionated distillates. Construction of the new Extraction Centre of Excellence is expected to begin immediately and the facility is scheduled to release its first concentrates by March 2019. The custom designed facility will house two Class 1/Division 1 extraction rooms as well as production, packaging facilities and will have the capacity to process in excess of 200,000 kgs of cannabis annually.

Last week Aphria completed the sale of 64,118,462 shares in Liberty Health Sciences, Inc. representing 100% of the Company’s outstanding investment in Liberty. As a result of the transaction, Aphria has divested its remaining U.S. cannabis assets from its balance sheet in accordance with the staff notice and requirements of the Toronto Stock Exchange. The Company says this has significantly improved its liquidity position while it continues to focus on the many opportunities within Canada and in other legal cannabis markets around the world.

On September 5 Aphria and Rapid Dose Therapeutics Inc. a Canadian bio-technology company focused on innovative drug delivery solutions, announced they have signed a non-binding Memorandum of Understanding (“MOU”) to Bring Innovative QuickStrip™ Oral Thin Strips to Aphria’s Portfolio of Medical and Adult-Use Brands.

We have a Monster Pick Coming. Subscribe Right Now!

Currently trading at a $3.6 billion market valuation Aphria has $59 million in the treasury, another $45 million in marketable securities and well over $1 billion in assets. Aphria has fast growing revenues reporting $12,026 in sales for the three months ended May 31, 2018 representing a 17% increase over the prior quarter’s revenue of $10,267. Aphria led by Vic Neufeld and a strong management team with production capacity set to exceed 250,000kgs by early 2019 holds a commanding position in the Canadian cannabis industry. There is huge demand for Aphria here and the next few weeks should be very exciting as we get closer to legal recreational cannabis on October 17. We will be updating on Aphria when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with Aphria.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: we hold no position in Aphria either long or short and we have not been compensated for this article.

More articles

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Latest article

Sign up now for our 100% FREE Penny Stock Newsletter

Privacy Policy. we will never share your email with anyone.